Acute Study on Muscle Soreness, Damage, and Performance
Primary Purpose
Soreness, Muscle, Performance Enhancing Product Use, Damage Muscle
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pre-workout plus and protein recovery plus
Placebo
Sponsored by
About this trial
This is an interventional other trial for Soreness, Muscle
Eligibility Criteria
Inclusion Criteria:
- Participant is an adult between the ages of 25-50 years
- Participant has a recorded BMI of 20-35 kg/m2
- Participant exercises less than 3 hours per week for at least 8 weeks preceding the study
- Participant has provided written and dated informed consent to participate in the study
- Participant is willing to and able to comply with the protocol
- Participant is apparently healthy and no reported metabolic disorders, heart disease, arrhythmias, thyroid disease, renal, hepatic, autoimmune or neurological diseases, as determined by a health history questionnaire
- Participant agrees to maintain current diet and exercise routine during the study
- Participant agrees to refrain from taking any anti-inflammatory supplement 48 hours prior to exercise (acute) or medications to prevent any further nutritional or drug related protection against exercise induced muscle damage
- Participant has a resting (seated for 5 minutes) blood pressure of systolic pressure between 140-90 mmHg and a diastolic pressure between 90-50 mmHg
Exclusion Criteria:
- Participant is currently enrolled in a separate clinical trial or weight loss program involving diet, exercise, physical activity, or the potential ingestion of an active drug or dietary supplement
- Participant is using, or has consistently used one of the following dietary supplements within 12 weeks prior to enrollment: Beta-alanine, Creatine, HMB, Carnosine, Vitamin D
- Participant has consistently consumed whey protein/plant protein and/or 1,000 mg of fish oil within the previous 4 weeks prior to enrollment
- Participant has gained or lost ≥ 8 lbs in the previous month
- Participant has a known allergy or sensitivity to the placebo or active ingredients
- Participant has used tobacco more than three days per week (on average) in the previous 6 months, or refuses to abstain from all tobacco use for the duration of the study
- Participant is pregnant or planning to become pregnant
- Participant has any musculoskeletal condition prohibiting them from participation
Sites / Locations
- University of North Carolina at Chapel Hill
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Pre-workout and Post-workout Product
Study Placebo
Arm Description
Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise
non-caloric powder mixed with water consumed within 30 minutes prior to exercise and within 15 minutes post exercise
Outcomes
Primary Outcome Measures
Performance
Change from baseline on performance by measuring countermovement vertical jump height using a jump mat and associated velocity using a linear transducer.
Secondary Outcome Measures
Muscle soreness
Change from baseline on muscle soreness using visual analog scale (a horizontal 100 mm line where zero will represent no soreness and one-hundred will represent maximum amount of soreness. Participants will be asked to place a single vertical that represents their current soreness. The scale will be measured with a calibrated ruler with the higher numbers representing more soreness.)
Creatine Kinase
Change from baseline on muscle damage by measuring creatine kinase
Isoprostanes
Change from baseline on muscle damage by measuring isoprostanes
Full Information
NCT ID
NCT04230226
First Posted
January 13, 2020
Last Updated
November 16, 2020
Sponsor
Pharmanex
Collaborators
University of North Carolina, Chapel Hill
1. Study Identification
Unique Protocol Identification Number
NCT04230226
Brief Title
Acute Study on Muscle Soreness, Damage, and Performance
Official Title
A Randomized, Double-blind, Placebo Controlled, Single-center Study to Determine the Effects of Pre-workout and Recovery Formulations on Soreness, Performance, Tolerance and Safety Outcomes in Healthy Adults Undergoing Training Program
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
January 21, 2020 (Actual)
Primary Completion Date
September 16, 2020 (Actual)
Study Completion Date
September 16, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pharmanex
Collaborators
University of North Carolina, Chapel Hill
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design. Participants will complete one enrollment visit, in which they will sign a consent form and complete a health history questionnaire. Participants will complete two interventions, with three visits each (6 visits total), in which a treatment beverage (pre/post supplement, or non-caloric placebo) will be consumed within 30 minutes prior to exercise and within 15 minutes post-exercise, in random order. Total time from enrollment to completion will be at least 14 days. Testing visits will be separated by a minimum of 7 days of rest to allow for recovery and washout, based on a half-life of ≤8 hours for all ingredients present in the supplement.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Soreness, Muscle, Performance Enhancing Product Use, Damage Muscle
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Pre-workout and Post-workout Product
Arm Type
Active Comparator
Arm Description
Pre-workout plus: a blend of caffeine, choline bitartrate, carbohydrate, HMB, vitamin D3 mixed with water and consumed within 30 minutes prior to exercise
Protein recovery plus: a blend of whey protein, caseinate, carbohydrate, vitamin C, alpha-tocopherol, vitamin D3, glucosamine mixed with water and consumed 15 minutes post exercise
Arm Title
Study Placebo
Arm Type
Placebo Comparator
Arm Description
non-caloric powder mixed with water consumed within 30 minutes prior to exercise and within 15 minutes post exercise
Intervention Type
Dietary Supplement
Intervention Name(s)
Pre-workout plus and protein recovery plus
Intervention Description
Study products consumed prior and after exercise
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo product consumed prior and after exercise
Primary Outcome Measure Information:
Title
Performance
Description
Change from baseline on performance by measuring countermovement vertical jump height using a jump mat and associated velocity using a linear transducer.
Time Frame
baseline, 24 hours, 48 hours
Secondary Outcome Measure Information:
Title
Muscle soreness
Description
Change from baseline on muscle soreness using visual analog scale (a horizontal 100 mm line where zero will represent no soreness and one-hundred will represent maximum amount of soreness. Participants will be asked to place a single vertical that represents their current soreness. The scale will be measured with a calibrated ruler with the higher numbers representing more soreness.)
Time Frame
baseline, 24 hours, 48 hours
Title
Creatine Kinase
Description
Change from baseline on muscle damage by measuring creatine kinase
Time Frame
baseline, 24 hours, 48 hours
Title
Isoprostanes
Description
Change from baseline on muscle damage by measuring isoprostanes
Time Frame
baseline, 24 hours, 48 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Participant is an adult between the ages of 25-50 years
Participant has a recorded BMI of 20-35 kg/m2
Participant exercises less than 3 hours per week for at least 8 weeks preceding the study
Participant has provided written and dated informed consent to participate in the study
Participant is willing to and able to comply with the protocol
Participant is apparently healthy and no reported metabolic disorders, heart disease, arrhythmias, thyroid disease, renal, hepatic, autoimmune or neurological diseases, as determined by a health history questionnaire
Participant agrees to maintain current diet and exercise routine during the study
Participant agrees to refrain from taking any anti-inflammatory supplement 48 hours prior to exercise (acute) or medications to prevent any further nutritional or drug related protection against exercise induced muscle damage
Participant has a resting (seated for 5 minutes) blood pressure of systolic pressure between 140-90 mmHg and a diastolic pressure between 90-50 mmHg
Exclusion Criteria:
Participant is currently enrolled in a separate clinical trial or weight loss program involving diet, exercise, physical activity, or the potential ingestion of an active drug or dietary supplement
Participant is using, or has consistently used one of the following dietary supplements within 12 weeks prior to enrollment: Beta-alanine, Creatine, HMB, Carnosine, Vitamin D
Participant has consistently consumed whey protein/plant protein and/or 1,000 mg of fish oil within the previous 4 weeks prior to enrollment
Participant has gained or lost ≥ 8 lbs in the previous month
Participant has a known allergy or sensitivity to the placebo or active ingredients
Participant has used tobacco more than three days per week (on average) in the previous 6 months, or refuses to abstain from all tobacco use for the duration of the study
Participant is pregnant or planning to become pregnant
Participant has any musculoskeletal condition prohibiting them from participation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abbie Smith-Ryan, PhD
Organizational Affiliation
University of North Carolina, Chapel Hill
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of North Carolina at Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Acute Study on Muscle Soreness, Damage, and Performance
We'll reach out to this number within 24 hrs